DK1461073T3 - Peptidagonister til prostataspecifikt antigen og anvendelser heraf - Google Patents
Peptidagonister til prostataspecifikt antigen og anvendelser herafInfo
- Publication number
- DK1461073T3 DK1461073T3 DK02789873.3T DK02789873T DK1461073T3 DK 1461073 T3 DK1461073 T3 DK 1461073T3 DK 02789873 T DK02789873 T DK 02789873T DK 1461073 T3 DK1461073 T3 DK 1461073T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptides
- psa
- nucleic acids
- prostate
- relates
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000556 agonist Substances 0.000 title abstract 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title abstract 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- -1 host cells Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 abstract 1
- 239000002987 primer (paints) Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33466901P | 2001-11-30 | 2001-11-30 | |
| US33457501P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037805 WO2003047506A2 (en) | 2001-11-30 | 2002-11-26 | Peptide agonists of prostate-specific antigen, and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1461073T3 true DK1461073T3 (da) | 2010-03-29 |
Family
ID=26989272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02789873.3T DK1461073T3 (da) | 2001-11-30 | 2002-11-26 | Peptidagonister til prostataspecifikt antigen og anvendelser heraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7247615B2 (enExample) |
| EP (1) | EP1461073B1 (enExample) |
| JP (1) | JP4364643B2 (enExample) |
| AT (1) | ATE454447T1 (enExample) |
| AU (1) | AU2002352913B2 (enExample) |
| CA (1) | CA2468258C (enExample) |
| DE (1) | DE60235041D1 (enExample) |
| DK (1) | DK1461073T3 (enExample) |
| ES (1) | ES2337454T3 (enExample) |
| WO (1) | WO2003047506A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902121B2 (en) * | 2001-07-02 | 2011-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | MHC-antigen arrays for detection and characterization of immune responses |
| US20070196346A1 (en) * | 2003-08-21 | 2007-08-23 | Brown Michael P | Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| AU2006244151B2 (en) | 2005-05-05 | 2012-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for detecting immune responses |
| EP1989224B1 (en) | 2006-02-24 | 2010-10-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Immunogenic peptides and methods of use |
| US20080095790A1 (en) * | 2006-10-24 | 2008-04-24 | Perambakam Supriya M | Methods of Treating Prostate Cancer |
| CN100522460C (zh) * | 2007-12-15 | 2009-08-05 | 江西江铃底盘股份有限公司 | 一种桥壳总成的焊接夹具及焊接工艺 |
| EP2477655A4 (en) * | 2009-09-14 | 2014-02-12 | Baylor Res Inst | VACCINES TREATED ON LANGERHANS CELLS |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| WO2013019445A2 (en) | 2011-07-29 | 2013-02-07 | Health Research, Inc. | Anti-angiogenic peptides and uses thereof |
| US9575053B2 (en) | 2012-03-30 | 2017-02-21 | Kyoto University | Urinary biomarker for use in test for prostate cancer |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| ES2738582T3 (es) | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| KR20260047644A (ko) | 2017-03-30 | 2026-04-08 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3853247A2 (en) | 2018-09-19 | 2021-07-28 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| MX2021012607A (es) | 2019-04-17 | 2022-03-11 | Alpine Immune Sciences Inc | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. |
| US20230190922A1 (en) | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| US20240279310A1 (en) | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| KR20250099778A (ko) | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| WO1998059073A1 (en) * | 1997-06-20 | 1998-12-30 | Mayo Foundation For Medical Education And Research | Method for detection of breast cancer |
| US20030175247A1 (en) * | 2000-05-12 | 2003-09-18 | Michael Salgaller | Method to increase class I presentation of exogenous antigens by human dendritic cells |
-
2002
- 2002-11-26 DE DE60235041T patent/DE60235041D1/de not_active Expired - Lifetime
- 2002-11-26 JP JP2003548767A patent/JP4364643B2/ja not_active Expired - Lifetime
- 2002-11-26 DK DK02789873.3T patent/DK1461073T3/da active
- 2002-11-26 ES ES02789873T patent/ES2337454T3/es not_active Expired - Lifetime
- 2002-11-26 EP EP02789873A patent/EP1461073B1/en not_active Expired - Lifetime
- 2002-11-26 US US10/497,003 patent/US7247615B2/en not_active Expired - Lifetime
- 2002-11-26 AT AT02789873T patent/ATE454447T1/de active
- 2002-11-26 WO PCT/US2002/037805 patent/WO2003047506A2/en not_active Ceased
- 2002-11-26 CA CA2468258A patent/CA2468258C/en not_active Expired - Lifetime
- 2002-11-26 AU AU2002352913A patent/AU2002352913B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002352913B2 (en) | 2008-05-29 |
| JP4364643B2 (ja) | 2009-11-18 |
| US20050054575A1 (en) | 2005-03-10 |
| CA2468258C (en) | 2011-10-11 |
| JP2005511037A (ja) | 2005-04-28 |
| EP1461073A2 (en) | 2004-09-29 |
| WO2003047506A3 (en) | 2004-07-15 |
| AU2002352913A1 (en) | 2003-06-17 |
| ATE454447T1 (de) | 2010-01-15 |
| EP1461073B1 (en) | 2010-01-06 |
| ES2337454T3 (es) | 2010-04-26 |
| CA2468258A1 (en) | 2003-06-12 |
| EP1461073A4 (en) | 2007-01-17 |
| US7247615B2 (en) | 2007-07-24 |
| WO2003047506A2 (en) | 2003-06-12 |
| DE60235041D1 (de) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1461073T3 (da) | Peptidagonister til prostataspecifikt antigen og anvendelser heraf | |
| KR102284493B1 (ko) | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| CN109803981B (zh) | 用于头颈鳞状细胞癌和其他癌症免疫治疗的新型肽和支架 | |
| HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
| MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
| WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| WO2001031019A3 (en) | Neisserial antigenic peptides | |
| AU2014317884B2 (en) | Immune system modulators | |
| MXPA04004417A (es) | Anticuerpo anti-tnf alfa modificado. | |
| WO2004024750A3 (en) | Cd44-binding ligands | |
| UA87106C2 (uk) | БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ РЕЦЕПТОР Nogo | |
| AU2020200990A1 (en) | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | |
| WO2005030793A3 (en) | Antibodies which bind human cxcr3 | |
| MX2023006773A (es) | Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos. | |
| MX2024015643A (es) | Polipéptidos de unión al antígeno contra el coronavirus 2 del síndrome respiratorio agudo grave (anti-sars-cov-2), complejos de polipéptidos y métodos de uso de estos | |
| MX2009003679A (es) | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. | |
| MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
| WO2002082091A3 (en) | Method for identification of proteins from intracellular bacteria | |
| WO2016144650A1 (en) | Immune system modulators and compositions | |
| KR102395995B1 (ko) | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| WO2005058944A3 (en) | Immunogenic peptides fragments of xage-1 | |
| AU2002336244A1 (en) | Trp2 isoform trp2-6b containing hla-a2-restricted epitopes | |
| Ghaly et al. | Advances in antimicrobial peptides: promising cancer treatments and vaccines | |
| WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| ATE525470T1 (de) | Antigene epitope des faktors viii, inhibitoren dagegen, und deren verwendungen |